Context Therapeutics Inc
CNTX1.293USD
+0.023+1.80%
Market hours （ET）Quotes delayed by 15 min
118.78MMarket Cap
LossP/E TTM
More Details of Context Therapeutics Inc Company
Context Therapeutics Inc. is a clinical-stage biopharmaceutical company, which is engaged in advancing T cell engaging (TCE) bispecific antibodies (bsAb) for solid tumors. It is building a portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (CLDN6) x CD3 TCE, CT-95, a Mesothelin (MSLN) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (Nectin-4) x CD3 TCE. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors and absent from or expressed at low levels in healthy adult tissues. CT-95 is intended to redirect T-cell-mediated lysis toward malignant cells expressing MSLN. MSLN is a membrane protein overexpressed in approximately 30% of cancers. Nectin-4 is a target for cancer therapy using a traditional antibody-drug conjugate, but it is also associated with certain adverse events, including neuropathy and rash. CT-202 is a pH-dependent TCE that is designed to be preferentially active within the acidic tumor microenvironment.
Context Therapeutics Inc Info
Ticker SymbolCNTX
Company nameContext Therapeutics Inc
IPO dateOct 20, 2021
CEOLehr (Martin)
Number of employees12
Security typeOrdinary Share
Fiscal year-endOct 20
Address2001 Market Street
CityPHILADELPHIA
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19103
Phone12672257416
Websitehttps://www.contexttherapeutics.com/
Ticker SymbolCNTX
IPO dateOct 20, 2021
CEOLehr (Martin)
Company Executives of Context Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Dr. Karen Chagin
Dr. Karen Chagin
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andy Pasternak
Mr. Andy Pasternak
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jennifer Minai-Azary
Ms. Jennifer Minai-Azary
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Karen L. Smith
Dr. Karen L. Smith
Independent Director
Independent Director
--
--
Mr. Alex Levit
Mr. Alex Levit
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Philip Kantoff, M.D.
Dr. Philip Kantoff, M.D.
Independent Director
Independent Director
--
--
Ms. Jennifer Evans Stacey, Esq.
Ms. Jennifer Evans Stacey, Esq.
Independent Director
Independent Director
--
--
Mr. Martin Lehr
Mr. Martin Lehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Linda West
Ms. Linda West
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Dr. Karen Chagin
Dr. Karen Chagin
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andy Pasternak
Mr. Andy Pasternak
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jennifer Minai-Azary
Ms. Jennifer Minai-Azary
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Karen L. Smith
Dr. Karen L. Smith
Independent Director
Independent Director
--
--
Mr. Alex Levit
Mr. Alex Levit
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MPM BioImpact LLC
16.01%
Avidity Partners Management LP
9.78%
Nextech Invest, Ltd.
8.08%
Deep Track Capital LP
8.08%
Blue Owl Capital Holdings LP
8.06%
Other
50.01%
Shareholders
Shareholders
Proportion
MPM BioImpact LLC
16.01%
Avidity Partners Management LP
9.78%
Nextech Invest, Ltd.
8.08%
Deep Track Capital LP
8.08%
Blue Owl Capital Holdings LP
8.06%
Other
50.01%
Shareholder Types
Shareholders
Proportion
Hedge Fund
29.56%
Investment Advisor/Hedge Fund
24.19%
Investment Advisor
21.48%
Individual Investor
1.25%
Family Office
0.12%
Venture Capital
0.01%
Other
23.39%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
80
69.14M
82.23%
--
2025Q3
80
69.14M
84.22%
+251.44K
2025Q2
81
68.88M
84.95%
-2.79M
2025Q1
78
71.67M
85.93%
-5.41M
2024Q4
78
73.10M
81.50%
+16.15M
2024Q3
73
57.92M
80.16%
-351.89K
2024Q2
65
58.27M
47.91%
+23.06M
2024Q1
50
5.18M
33.39%
-154.44K
2023Q4
53
4.80M
32.90%
+979.98K
2023Q3
53
3.82M
30.42%
+339.39K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
MPM BioImpact LLC
14.71M
16.39%
--
--
Jun 30, 2025
Avidity Partners Management LP
7.48M
8.34%
+55.00
+0.00%
Jun 30, 2025
Nextech Invest, Ltd.
7.42M
8.27%
--
--
Jun 30, 2025
Deep Track Capital LP
7.42M
8.27%
--
--
Jun 30, 2025
Blue Owl Capital Holdings LP
7.41M
8.26%
+40.00K
+0.54%
Jun 30, 2025
Great Point Partners, LLC
4.68M
5.22%
--
--
Jun 30, 2025
Franklin Advisers, Inc.
4.00M
4.46%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
3.36M
3.75%
+107.11K
+3.29%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
2.44M
2.72%
--
--
Jun 30, 2025
Alyeska Investment Group, L.P.
1.66M
1.85%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Context Therapeutics Inc?
The top five shareholders of Context Therapeutics Inc are:
MPM BioImpact LLC holds 14.71M shares, accounting for 16.39% of the total shares.
Avidity Partners Management LP holds 7.48M shares, accounting for 8.34% of the total shares.
Nextech Invest, Ltd. holds 7.42M shares, accounting for 8.27% of the total shares.
Deep Track Capital LP holds 7.42M shares, accounting for 8.27% of the total shares.
Blue Owl Capital Holdings LP holds 7.41M shares, accounting for 8.26% of the total shares.
MPM BioImpact LLC holds 14.71M shares, accounting for 16.39% of the total shares.
Avidity Partners Management LP holds 7.48M shares, accounting for 8.34% of the total shares.
Nextech Invest, Ltd. holds 7.42M shares, accounting for 8.27% of the total shares.
Deep Track Capital LP holds 7.42M shares, accounting for 8.27% of the total shares.
Blue Owl Capital Holdings LP holds 7.41M shares, accounting for 8.26% of the total shares.
What are the top three shareholder types of Context Therapeutics Inc?
The top three shareholder types of Context Therapeutics Inc are:
MPM BioImpact LLC
Avidity Partners Management LP
Nextech Invest, Ltd.
MPM BioImpact LLC
Avidity Partners Management LP
Nextech Invest, Ltd.
How many institutions hold shares of Context Therapeutics Inc (CNTX)?
As of 2025Q4, 80 institutions hold shares of Context Therapeutics Inc, with a combined market value of approximately 69.14M, accounting for 82.23% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.99%.
What is the biggest source of revenue for Context Therapeutics Inc?
In --, the -- business generated the highest revenue for Context Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
